About Us - Black Light Surgical

Though

light

can shine everywhere,

For us, it

Glows

Differently

Light is the basis of our technology and is our platform for innovation, changing the way we see disease. For us, it’s proof of a brighter future for cancer detection and the lives of innumerable patients. We have taken the allegorical sense of light to heart—an agent that drives out darkness and allows others to see—and have applied it to the medical field, keeping hope and compassion at the core of everything we do.

Though

light

can shine everywhere,

For Us, It

Glows

Differently

Our goal is to

use biochemical imaging

technology to radically improve the quality of cancer surgeries outcomes.

Blacklight Surgical is a privately-held early-stage medical device company pursuing development and commercialization for technology initially conceived in the Department of Neurosurgery at Cedars Sinai Medical center in Los Angeles.

The company’s goal was initially to use its unique biochemical imaging technology to radically improve the quality of outcomes in brain cancer surgery, where the survival rates have unfortunately been highly unfavorable. After early success in the intra-operative detection of cancerous tissue in glioblastoma clinical studies, followed by outstanding results in a breast cancer clinical trial, the company decided to focus its short-term work in the field of breast cancer surgery because of the urgency and extent of the need to improve results. We felt compelled to change the current outcomes in which one-third of the women have to undergo a second surgery after their first lumpectomy procedure because excisable cancer was left behind.

Our technology has been labeled by the FDA as a

“Breakthrough Device”

Our technology has been labeled by the FDA as a

“Breakthrough Device”

Our Success

We are pleased with the substantial progress we have made in the breast surgery application, which has resulted in the technology being labeled a ‘breakthrough device’ by the FDA, thereby facilitating its path to marketing approval.

Our success to date in both brain and breast cancer detection has convinced us that our technology indeed forms a basis for a novel platform that can be extended to include detection of commonly occurring forms of cancer such as colon, lung, cervical, prostate, uterine, and bladder. We believe it can also enhance colonoscopy procedures and serve as an accurate and easy-to-use screening tool for such conditions as skin cancer.

Interested in

Our Technology?

Find out what’s the next chapter in
biochemical imaging and how you can
become a part of it.

Interested In Our Technology?

Find out what’s the next chapter in
biochemical imaging and how you can become a part of it.